- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02808949
Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Alabama CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Women must meet all of the following criteria (by self-report, unless otherwise indicated) to be eligible for inclusion in the study:
- Age 18 or older at screening as verified per site SOP
- Per participant report, at least 6 weeks postpartum at Enrollment
- Willing and able to provide written informed consent to be screened for and take part in the study
- Willing and able to provide adequate locator information, as defined in site SOP
- Willing and able to communicate in spoken and written English
- HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix II and willing to receive HIV test results Note: HIV-1/2 screening may be omitted at Enrollment if the time between Screening and Enrollment is < 30 days
- Prior to Enrollment, breastfeeding of child has stopped
- Participant has no intention of providing expressed breast milk to her child(ren) or to others for consumption after initiation of study product Note: Providing stored breast milk to child(ren) that has been expressed prior to study product exposure is not exclusionary
- Willing and able to express breast milk at least twice daily for the duration of study drug exposure
- Per participant report, using an effective method of contraception at Enrollment, and intending to continue the use of an effective method for the duration of study participation. Effective methods for MTN-029/IPM 039 include: hormonal methods (except contraceptive VRs), intrauterine device (IUD) inserted at least 28 days prior to enrollment, engages in sex exclusively with women, sterilized (self or partner), or sexually abstinent for the past 90 days
- Women over the age of 21 (inclusive) must have documentation of a satisfactory Pap within the past 3 years prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies (Addendum 1 to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, November 2007), or satisfactory evaluation with no treatment required of Grade 1 or higher Pap result
- At Screening, participant states a willingness to refrain from receptive sexual activity (including penile-vaginal intercourse, anal intercourse, receptive oral intercourse, finger stimulation) and from inserting any non-study objects into the vagina (including tampons, sex toys, female condoms, diaphragms, menstrual cups, cervical caps or any other vaginal barrier method, etc.), for 24 hours prior to each clinic visit.
- At Screening, participant states a willingness to refrain from the use of vaginal products, including, spermicides, lubricants, contraceptive VRs, douches, vaginal medications, etc., for the duration of study participation
- Per participant report at Screening and Enrollment, agrees not to participate in other research studies involving drugs, medical devices, vaginal products, vaccines or breast milk sampling for the duration of study participation Note: Participation in observational studies is not exclusionary
Exclusion Criteria:
Women who meet any of the following criteria (by self-report, unless otherwise indicated) will be excluded from the study:
Participant report of any of the following:
- History of adverse reaction to any component of dapivirine VR
- Participation in investigational drug or device trial within 30 days prior to the Enrollment Visit (Day 0)
- Use of vaginal medication(s) 5 days prior to Enrollment (Day 0)
- Complication of lactation requiring treatment, e.g., mastitis
- At the time of Screening and Enrollment, clinical evidence of milk supply less than 1 ounce per expression
- As determined by the IoR/designee, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease
Grade 2 or higher AST/ALT at Screening Visit:
Note: Otherwise eligible participants with an exclusionary AST/ALT may be retested during the screening process.
- Positive urine pregnancy test at screening or enrollment
- Diagnosed with urinary tract infection (UTI) at Screening or Enrollment Note: Otherwise eligible participants diagnosed with UTI during screening are offered treatment and may be enrolled after completing treatment and all symptoms have resolved.
- Diagnosed with an STI or a reproductive tract infection (RTI) requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines at Screening or Enrollment
On pelvic exam, any of the following findings:
- Incomplete postpartum involution of the uterus
- Clinically apparent Grade 2 or higher pelvic exam finding (observed by study staff)
- Use of oral and/or vaginal preparations of antibiotic or antifungal medications within 5 days of Enrollment
- At Screening or Enrollment, any social or medical condition that, in the investigator's opinion, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Age Groups
Dapivirine levels in breast milk will be measured in 16 participants.
All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
|
Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days.
Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: 14 Days
|
To assess the pharmacokinetics of dapivirine vaginal ring used for 14 consecutive days in lactating women
|
14 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of dapivirine ring in lactating women
Time Frame: 14 days
|
To assess safety and tolerability of dapivirine vaginal ring used for 14 consecutive days in lactating women
|
14 days
|
Adherence to dapivirine vaginal ring use in lactating women
Time Frame: 14 days
|
To assess adherence to dapivirine vaginal ring use in lactating women
|
14 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Craig Hoesley, MD, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Dapivirine
Other Study ID Numbers
- MTN-029/IPM 039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on Dapivirine
-
International Partnership for Microbicides, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedHIV-1-infectionUnited States
-
International Partnership for Microbicides, Inc.Completed
-
International Partnership for Microbicides, Inc.CompletedPharmaokinetics
-
International Partnership for Microbicides, Inc.Completed
-
International Partnership for Microbicides, Inc.CompletedHIV-1 InfectionsUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV InfectionsBelgium
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV Infections | Acquired Immunodeficiency SyndromeKenya, Malawi, Rwanda, South Africa, Tanzania
-
International Partnership for Microbicides, Inc.CompletedHIV InfectionsBelgium
-
International Partnership for Microbicides, Inc.Completed